 Home > Active Ingredient News > Endocrine System > Front Oncol: The impact of blood glucose control on the survival of advanced non-small cell lung cancer (NSCLC) patients with diabetes

Front Oncol: The impact of blood glucose control on the survival of advanced non-small cell lung cancer (NSCLC) patients with diabetes

 Last Update: 2021-12-02
 Source: Internet
 Author: User

Tags

data base analysis

diabetes oral medication

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Diabetes mellitus (DM) is one of the common underlying diseases in cancer patients

A total of 1279 patients with advanced NSCLC , including 300 patients (23.

Among 1279 cases of advanced NSCLC , 300 cases (23.

Multivariate Cox regression analysis also showed that diabetes status (HR: 0.

In diabetic patients, according to the stratified analysis of HbA1c levels, the OS of patients with high HbA1c levels was significantly lower than that of patients with intermediate levels (high level vs low level: p=0.

Reveal the continuing relationship between HbA1c and OS through RCS .

RCS to reveal HbA1c and OS ongoing relationship between the RCS to reveal HbA1c and OS sustained relationship between

X-tile analysis showed that the best cut-off value of HbA1c was 6.

X-tile analysis shows that the best cut-off value of HbA1c is 6.

Well-controlled diabetes is defined as HbA1c≤6.
6%
.
All patients were divided into three groups (non-diabetic group, diabetes mellitus with HbA1c≤6.
6% group and diabetes mellitus with HbA1c>6.
6% group) , and the survival benefit of optimal blood sugar control was analyzed
.
The median OS (95% CI) of the non-diabetic group, the diabetic HbA1c≤6.
6% group, and the diabetic HbA1c>6.
6% group were 22.
22 (20.
01-24.
43), 25.
28 (21.
79-28.
77), and 15.
45 (7.
57-23.
33), respectively.
) Months
.
The OS of patients with well-controlled diabetes (HbA1c≤6.
6%) was similar to that of non-diabetic patients (HR (95% CI): 0.
90 (0.
76-1.
08), P = 0.
273)
.
Well-controlled diabetes is defined as HbA1c≤6.
6%
.
All patients were divided into three groups (non-diabetic group, diabetes mellitus with HbA1c≤6.
6% group and diabetes mellitus with HbA1c>6.
6% group) , and the survival benefit of optimal blood sugar control was analyzed
.
The median OS (95% CI) of the non-diabetic group, the diabetic HbA1c≤6.
6% group, and the diabetic HbA1c>6.
6% group were 22.
22 (20.
01-24.
43), 25.
28 (21.
79-28.
77), and 15.
45 (7.
57-23.
33), respectively.
) Months
.
The OS of patients with well-controlled diabetes (HbA1c≤6.
6%) was similar to that of non-diabetic patients (HR (95% CI): 0.
90 (0.
76-1.
08), P = 0.
273)
.
The OS of patients with well-controlled diabetes (HbA1c≤6.
6%) is similar to that of non-diabetic patients (HR (95% CI): 0.
90 (0.
76-1.
08), P = 0.
273)
.
The OS of patients with diabetes and HbA1c>6.
6% was higher than that of non-diabetic patients (HR (95% CI): 1.
70 (1.
24-2.
34), P = 0.
001) and well-controlled diabetes (HbA1c≤6.
6%) patients (HR (95% CI) CI): 1.
88 (1.
33-2.
67), P=0.
001) poor
.
Subgroup analysis showed that compared with non-diabetic patients, all subgroups of diabetic patients with well-controlled HbA1c had a survival benefit
.
The OS of patients with diabetes mellitus and HbA1c>6.
6% was higher than that of non-diabetic patients (HR (95% CI): 1.
70 (1.
24-2.
34), P = 0.
001) and well-controlled diabetes (HbA1c≤6.
6%) patients (HR (95% CI) CI): 1.
88 (1.
33-2.
67), P=0.
001) poor
.
Subgroup analysis showed that compared with non-diabetic patients, all subgroups of diabetic patients with well-controlled HbA1c had a survival benefit
.

The effect of different stratification of HbA1c on prognosis

The effect of different stratification of HbA1c on the prognosis The effect of different stratification of HbA1c on the prognosis

In summary, studies have shown that impaired blood glucose levels have a negative impact on the survival of patients with advanced NSCLC, and proper blood glucose control (HbA1c≤6.
6%) can improve OS
.
In summary, studies have shown that impaired blood glucose levels have a negative impact on the survival of patients with advanced NSCLC, and proper blood glucose control (HbA1c≤6.
6%) can improve OS
.

Original source:

Qian J, Wang W, Wang L, Lu J, Zhang L, Zhang B, Wang S, Nie W, Zhang Y, Lou Y and Han B (2021) The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus.
Front.
Oncol.
11:745150.
doi: 10.
3389/fonc.
2021.
745150

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.